Immunovant Ownership

Immunovant has a total of 146.78 Million outstanding shares. Over half of Immunovant's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Also note that almost fourteen million nine hundred eighty-six thousand seven hundred fourty-eight invesors are currently shorting Immunovant expressing very little confidence in its future performance. Some institutional investors establish a significant position in stocks such as Immunovant in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Immunovant, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Dividend Paid And Capex Coverage Ratio is likely to gain to -548.98 in 2024. Common Stock Shares Outstanding is likely to drop to about 80.8 M in 2024. Net Loss is likely to drop to -472.5 in 2024. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.